These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6685483)

  • 21. Effects of 2,5-dimethoxy-4-methylamphetamine on the behavior of rats in competition for food.
    Uyeno ET
    Int Pharmacopsychiatry; 1972; 7(1-4):244-8. PubMed ID: 4681210
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity.
    Adams LM; Geyer MA
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(2):121-32. PubMed ID: 3858911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.
    Muschamp JW; Regina MJ; Hull EM; Winter JC; Rabin RA
    Brain Res; 2004 Oct; 1023(1):134-40. PubMed ID: 15364028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross tolerance or tachyphylaxis among various psychotomimetic agents on cats.
    Wallach MB; Hine B; Gershon S
    Eur J Pharmacol; 1974 Nov; 29(1):89-92. PubMed ID: 4435048
    [No Abstract]   [Full Text] [Related]  

  • 25. The effects of lysergic acid diethylamide and mescaline-derived hallucinogens on sensory-integrative function: tactile startle.
    Geyer MA; Petersen LR; Rose GJ; Horwitt DD; Light RK; Adams LM; Zook JA; Hawkins RL; Mandell AJ
    J Pharmacol Exp Ther; 1978 Dec; 207(3):837-47. PubMed ID: 731434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profiles of psychedelic drugs: 10. DOB.
    Shulgin A
    J Psychoactive Drugs; 1981; 13(1):99. PubMed ID: 7277091
    [No Abstract]   [Full Text] [Related]  

  • 28. Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue.
    Nichols DE; Woodard R; Hathaway BA; Lowy MT; Yom KW
    J Med Chem; 1979 Apr; 22(4):458-60. PubMed ID: 430485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    Pharmacol Biochem Behav; 1977 Oct; 7(4):307-10. PubMed ID: 928488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LSD or DOB?
    Davis WM
    Am J Psychiatry; 1982 Dec; 139(12):1649. PubMed ID: 7149079
    [No Abstract]   [Full Text] [Related]  

  • 31. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 32. Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane.
    Oberlender RA; Kothari PJ; Nichols DE; Zabik JE
    J Med Chem; 1984 Jun; 27(6):788-92. PubMed ID: 6737421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain.
    McKenna DJ; Saavedra JM
    Eur J Pharmacol; 1987 Oct; 142(2):313-5. PubMed ID: 3691644
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

  • 35. A reevaluation of psychotomimetic amphetamine derivatives in humans.
    Cassels BK; Gómez-Jeria JS
    J Psychoactive Drugs; 1985; 17(2):129-30. PubMed ID: 4020537
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative effects of hallucinogenic drugs on behavior of the cat.
    Jacobs BL; Trulson ME; Stark AD; Christoph GR
    Commun Psychopharmacol; 1977; 1(3):243-54. PubMed ID: 272265
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25.
    Gorodetzky CW; Isbell H
    Psychopharmacologia; 1964 Sep; 6(3):229-33. PubMed ID: 5319153
    [No Abstract]   [Full Text] [Related]  

  • 38. Photoelectron spectroscopic studies of hallucinogens: the use of ionization potentials in QSAR.
    Domelsmith LN; Houk KN
    NIDA Res Monogr; 1978; (22):423-40. PubMed ID: 101887
    [No Abstract]   [Full Text] [Related]  

  • 39. Congeners of DOM: effect of distribution of the evaluation of pharmacologic data.
    Barfknecht CF; Caputo JF; Tobin MB; Dyer DC; Standirdge RT; Howell HG; Goodwin WR; Partyka RA; Gylys JA; Cavanagh RL
    NIDA Res Monogr; 1978; (22):16-26. PubMed ID: 101880
    [No Abstract]   [Full Text] [Related]  

  • 40. The lack of correlation between hallucinogenesis and inhibition of axoplasmic transport.
    Paulson JC; McClure WO
    Mol Pharmacol; 1974 May; 10(3):419-24. PubMed ID: 4137280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.